| Class / Patent application number | Description | Number of patent applications / Date published |
|---|
| 514253110 | Chalcogen hetero ring attached directly or indirectly to the piperazine ring by nonionic bonding | 20 |
| 20090082362 | Use of capsaicin receptor antagonists to treat symptoms of tear gas exposure - Disclosed are diaryl piperazines and related compounds. These compounds are selective modulators of capsaicin receptors, including human capsaicin receptors, that are, therefore, useful in the treatment of a chronic and acute pain conditions, itch and urinary incontinence. Methods of treatment of such disorders and well as packaged pharmaceutical compositions are also provided. Compounds of the invention are also useful as probes for the localization of capsaicin receptors and as standards in assays for capsaicin receptor binding and capsaicin receptor mediated cation conductance. Methods of using the compounds in receptor localization studies are given. | 03-26-2009 |
| 20090099199 | ORGANIC COMPOUNDS - The invention relates to compound of the formula I | 04-16-2009 |
| 20090215794 | SEROTONERGIC AGENTS - Novel piperazine derivatives are provided having the formula | 08-27-2009 |
| 20090247544 | Certain Chemical Entities, Compositions and Methods - Certain substituted urea derivatives modulate diskeletal myosin, skeletal actin, skeletal tropomyosin, skeletal troponin C, skeletal troponin I, skeletal troponin T, and skeletal muscle, including fragments and isoforms thereof, as well as the skeletal sarcomere, and are useful in the treatment of obesity, sarcopenia, wasting syndrome, frailty, muscle spasm, cachexia, neuromuscular diseases (e.g., amyotrophic lateral sclerosis, spinal muscular atrophy, familial or acquired myopathies or muscular dystrophies), post-surgical and post-traumatic muscle weakness, and other conditions. | 10-01-2009 |
| 20100056541 | BIPHENYL COMPOUNDS USEFUL AS MUSCARINIC RECEPTOR ANTAGONISTS - The invention provides compounds of formula I: | 03-04-2010 |
| 20100093753 | BIPHENYL COMPOUNDS USEFUL AS MUSCARINIC RECEPTOR ANTAGONISTS - The invention provides compounds of formula I: | 04-15-2010 |
| 20100331341 | 2-CARBOXAMIDE-7-PIPERAZINYL-BENZOFURAN DERIVATIVES 774 - The present invention relates to compounds of formula (I), | 12-30-2010 |
| 20110009420 | Histamine H3 Receptor Ligands - The present invention provides compounds of the formula | 01-13-2011 |
| 20110009421 | COMPOUND HAVING 6-MEMBERED AROMATIC RING - An object of the present invention is to provide an agent for preventing or treating schizophrenia or the like, wherein the compound of the present invention has GPRS2 agonist activity. | 01-13-2011 |
| 20110144122 | DERIVATIVES OF 2-OXOALKYL-1-PIPERAZIN-2-ONE, PREPARATION METHOD THEREOF AND THERAPEUTIC USE OF SAME - The present invention relates to derivatives of 4-{2-[phenyl-3,6-dihydropyridin-1-yl]-2-oxoalkyl}-1-piperazin-2-one and 4-{2-[phenyl-2,5-dihydropyrrol-1-yl]-2-oxoalkyl}-1-piperazin-2-one having general formula (I): | 06-16-2011 |
| 20110263611 | Kinase Inhibitors - The present invention relates to drug delivery systems comprising ocular implant, which include organic molecules, capable of modulating tyrosine kinase signal transduction in order to regulate, modulate and/or inhibit abnormal cell proliferation, in combination with a polymer, which polymer serves to control, modify, modulate and/or slow the release of the therapeutic component into the environment of the eye in which said composite is placed. | 10-27-2011 |
| 20120270882 | FLUORINATED DERIVATES OF 3-HYDROXYPYRIDIN-4-ONES - Provided are compounds of Formula I which are derivatives of 3-Hydroxypyridin-4-ones. The compounds may be used in treatment of a medical condition related to a toxic concentration of iron. The compounds may be used for preparation of a medicament for treatment of a medical condition related to a toxic concentration of iron. The medical condition related to a toxic concentration of iron may be selected from the group consisting of: cancer, pulmonary disease, progressive kidney disease and Frederich's Ataxia. | 10-25-2012 |
| 20130053398 | MODULATORS OF FATTY ACID AMIDE HYDROLASE - 4-(2,2-Difluoro-benzo[1,3]dioxol-5-ylmethyl)-piperazine-1-carboxylic acid (4-chloro-pyridin-3-yl)-amide is described, which is useful as a FAAH modulator. 4-(2,2-Difluoro-benzo[1,3]dioxol-5-ylmethyl)-piperazine-1-carboxylic acid (4-chloro-pyridin-3-yl)-amide may be used in pharmaceutical compositions and methods for the treatment of disease states, disorders, and conditions mediated by fatty acid amide hydrolase (FAAH) activity, such as anxiety, pain, inflammation, sleep disorders, eating disorders, energy metabolism disorders, and movement disorders (e.g., multiple sclerosis). A method of synthesizing 4-(2,2-difluoro-benzo[1,3]dioxol-5-ylmethyl)-piperazine-1-carboxylic acid (4-chloro-pyridin-3-yl)-amide is also disclosed. | 02-28-2013 |
| 20130237547 | SULFAMIDES AS TRPM8 MODULATORS - Disclosed are compounds, compositions and methods for treating various diseases, syndromes, conditions and disorders, including pain. Such compounds are represented by Formula I as follows: | 09-12-2013 |
| 20130345235 | PHENOXY THIOPHENE SULFONAMIDES AND THEIR USE AS INHIBITORS OF GLUCURONIDASE - This invention relates generally to compounds that are glucuronidase inhibitors. Glucuronidase inhibitors described include phenoxy thiophene sulfonamides. Other compounds, for instance pyridine sulfonyls, benzene sulfonyls, thiophene sulfonyls, thiazole sulfonyls, thiophene carbonyls, and thiazole carbonyls, are also contemplated. Also contemplated are compositions including one or more of such compounds for use inhibiting glucuronidase and methods of using one or more of such compounds as a co-drug to be used in combination with the anticancer drug CPT-11. | 12-26-2013 |
| 20140200225 | PROTEASE INHIBITORS - A compound of formula (I) wherein R | 07-17-2014 |
| 20150099761 | MODULATORS OF FATTY ACID AMIDE HYDROLASE - 4-(2,2-Difluoro-benzo[1,3]dioxol-5-ylmethyl)-piperazine-1-carboxylic acid (4-chloro-pyridin-3-yl)-amide is described, which is useful as a FAAH modulator. 4-(2,2-Difluoro-benzo[1,3]dioxol-5-ylmethyl)-piperazine-1-carboxylic acid (4-chloro-pyridin-3-yl)-amide may be used in pharmaceutical compositions and methods for the treatment of disease states, disorders, and conditions mediated by fatty acid amide hydrolase (FAAH) activity, such as anxiety, pain, inflammation, sleep disorders, eating disorders, energy metabolism disorders, and movement disorders (e.g., multiple sclerosis). A method of synthesizing 4-(2,2-difluoro-benzo[1,3]dioxol-5-ylmethyl)-piperazine-1-carboxylic acid (4-chloro-pyridin-3-yl)-amide is also disclosed. | 04-09-2015 |
| 20160016941 | NOVEL 5-HYDROXYTRYPTAMINE RECEPTOR 7 ACTIVITY MODULATORS AND THEIR METHOD OF USE - Pharmaceutical compositions of the invention comprise functionalized lactone derivatives having a disease-modifying action in the treatment of diseases associated with dysregulation of 5-hydroxytryptamine receptor 7 activity. | 01-21-2016 |
| 20160168134 | NAMPT INHIBITORS | 06-16-2016 |
| 20160375016 | METHODS FOR REDUCING ANXIETY AND IMPULSIVITY IN SUBJECTS INITIATING TREATMENT WITH SEROTONIN REUPTAKE INHIBITORS - The present invention provides compositions and uses thereof for reducing anxiety and/or impulsivity, including, for example, suicidality, in a subject undergoing treatment with a serotonin reuptake inhibitor (SRI) comprising administering to the subject an effective amount of a SRI and an effective amount of a 5-HT1A receptor partial agonist/antagonist. In addition, the present invention provides dosing regimens for various SSRIs which can also reduce anxiety and/or impulsivity, including, for example, suicidality in a subject undergoing treatment with an SSRI. Kits including daily dosing regimens of various SSRIs are also provided. | 12-29-2016 |
